DE69435253D1 - Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen - Google Patents

Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen

Info

Publication number
DE69435253D1
DE69435253D1 DE69435253T DE69435253T DE69435253D1 DE 69435253 D1 DE69435253 D1 DE 69435253D1 DE 69435253 T DE69435253 T DE 69435253T DE 69435253 T DE69435253 T DE 69435253T DE 69435253 D1 DE69435253 D1 DE 69435253D1
Authority
DE
Germany
Prior art keywords
botulism
serotypes
treatment
conditions
various
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69435253T
Other languages
English (en)
Inventor
Roger K Aoki
Michael W Grayston
Steven R Carlson
Judith M Leon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DE69435253D1 publication Critical patent/DE69435253D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69435253T 1993-06-10 1994-06-07 Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen Expired - Lifetime DE69435253D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7504893A 1993-06-10 1993-06-10

Publications (1)

Publication Number Publication Date
DE69435253D1 true DE69435253D1 (de) 2009-12-31

Family

ID=22123211

Family Applications (6)

Application Number Title Priority Date Filing Date
DE69429619T Expired - Lifetime DE69429619T2 (de) 1993-06-10 1994-06-07 Behandlung von neuromusculaeren stoerungen und zustaenden mit botulism serotyp e
DE122009000066C Active DE122009000066I2 (de) 1993-06-10 1994-06-07 Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen
DE69435253T Expired - Lifetime DE69435253D1 (de) 1993-06-10 1994-06-07 Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
DE69435254T Expired - Lifetime DE69435254D1 (de) 1993-06-10 1994-06-07 Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
DE69435235T Expired - Lifetime DE69435235D1 (de) 1993-06-10 1994-06-07 Behandlung von neuromuskularen Störungen und Zuständen mit verschiedenen botulinen Serotypen
DE69435284T Expired - Lifetime DE69435284D1 (de) 1993-06-10 1994-06-07 Behandlung neuromuskulärer Erkrankungen und Zustände mit verschiedenem Botulin-Serotyp

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69429619T Expired - Lifetime DE69429619T2 (de) 1993-06-10 1994-06-07 Behandlung von neuromusculaeren stoerungen und zustaenden mit botulism serotyp e
DE122009000066C Active DE122009000066I2 (de) 1993-06-10 1994-06-07 Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen

Family Applications After (3)

Application Number Title Priority Date Filing Date
DE69435254T Expired - Lifetime DE69435254D1 (de) 1993-06-10 1994-06-07 Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
DE69435235T Expired - Lifetime DE69435235D1 (de) 1993-06-10 1994-06-07 Behandlung von neuromuskularen Störungen und Zuständen mit verschiedenen botulinen Serotypen
DE69435284T Expired - Lifetime DE69435284D1 (de) 1993-06-10 1994-06-07 Behandlung neuromuskulärer Erkrankungen und Zustände mit verschiedenem Botulin-Serotyp

Country Status (9)

Country Link
US (3) US6872397B2 (de)
EP (7) EP1374886B1 (de)
JP (4) JPH08511536A (de)
AU (1) AU689115B2 (de)
CA (3) CA2332406C (de)
DE (6) DE69429619T2 (de)
ES (5) ES2329232T3 (de)
HK (1) HK1061648A1 (de)
WO (1) WO1994028922A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
DE69429619T2 (de) * 1993-06-10 2002-09-12 Allergan Inc Behandlung von neuromusculaeren stoerungen und zustaenden mit botulism serotyp e
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
DE69427869T2 (de) * 1993-12-28 2002-04-11 Allergan Sales Inc Botulinumtoxine zur behandlung von hyperhydrosis
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
ES2198484T3 (es) * 1995-06-06 2004-02-01 L. Bruce Pearce Composiciones y procedimientos mejorados para quimiodenervacion usando neurotoxinas.
AU2340299A (en) 1998-01-26 1999-08-09 University Of Massachusetts Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
AU2003272800A1 (en) * 2002-10-01 2004-04-23 University Of Maryland Methods for identifying inhibitors of botulinum neurotoxins
MXPA05009424A (es) * 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Tratamiento de chalazion cronico y hordeolum con la toxina botulinica.
US20040226556A1 (en) * 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US20080274480A1 (en) * 2004-08-04 2008-11-06 Allergan, Inc. Botulinum Toxin Type a Immunoresistant Assay
ATE416191T1 (de) 2004-09-01 2008-12-15 Allergan Inc Abbaubare clostridientoxine
EP2316847A3 (de) 2005-03-15 2012-01-18 Allergan, Inc. Modifizierte Clostridientoxine mit erhöhter Targeting-Kapazität für endogene Clostridientoxin-Rezeptorsysteme
AU2006340711C1 (en) 2005-04-05 2013-02-07 Allergan, Inc. Clostridial toxin activity assays
EP1906923B1 (de) 2005-07-22 2018-01-24 The Foundry, LLC Systeme und verfahren zur freisetzung eines therapeutischen wirkstoffes
US7655243B2 (en) 2005-07-22 2010-02-02 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
CA2601537A1 (en) 2006-03-14 2007-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US20110033431A1 (en) * 2008-03-31 2011-02-10 The Chemo-Sero-Therapeutic Research Institute Type a2 botulinum toxin preparation
CA2723806C (en) 2008-05-09 2022-05-31 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
JP5843777B2 (ja) 2009-10-27 2016-01-13 ホライラ， インコーポレイテッド 冷却可能なエネルギー放出アセンブリを有する送達デバイス
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
AU2010319477A1 (en) 2009-11-11 2012-05-24 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
KR102113994B1 (ko) 2012-04-13 2020-05-25 루브리졸 어드밴스드 머티어리얼스, 인코포레이티드 신경세포 세포외배출(ii)을 억제하는 화합물
EP2649984A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose
EP2649983A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (II)
EP2649985A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (III)
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
US10647750B2 (en) 2015-01-09 2020-05-12 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (de) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Herstellung von aktivierten clostridien-neurotoxinen
CN109790204A (zh) 2016-09-29 2019-05-21 益普生生物制药有限公司 杂合神经毒素
US20210187194A1 (en) 2018-02-26 2021-06-24 Ipsen Biopharm Limited Use of Ultrasound to Guide Injection of Non-cytotoxic Protease
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2373454A (en) * 1943-07-09 1945-04-10 Squibb & Sons Inc Method of preparing tetanus toxin
US2719102A (en) * 1949-10-28 1955-09-27 Corn States Serum Company Clostridium perfringens toxoid and process of making the same
US3132995A (en) * 1961-10-20 1964-05-12 Carter Prod Inc Endotoxin fractions and method for producing same
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5055291A (en) * 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4932936A (en) * 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5401243A (en) 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5183462A (en) 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
FR2692475B1 (fr) 1992-06-19 2000-04-21 Montpellier Chirurgie Prothese totale du genou.
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
DE69429619T2 (de) * 1993-06-10 2002-09-12 Allergan Inc Behandlung von neuromusculaeren stoerungen und zustaenden mit botulism serotyp e
DE69427869T2 (de) 1993-12-28 2002-04-11 Allergan Sales Inc Botulinumtoxine zur behandlung von hyperhydrosis

Also Published As

Publication number Publication date
CA2332406C (en) 2005-01-04
DE69435284D1 (de) 2010-04-29
EP0702561B1 (de) 2002-01-09
ES2329232T3 (es) 2009-11-24
EP1099445A2 (de) 2001-05-16
US20010012833A1 (en) 2001-08-09
JPH08511536A (ja) 1996-12-03
US6872397B2 (en) 2005-03-29
AU7087894A (en) 1995-01-03
ES2341140T3 (es) 2010-06-15
EP1512411B1 (de) 2009-11-18
EP1508336B1 (de) 2009-11-18
EP1374886A2 (de) 2004-01-02
EP1512411A1 (de) 2005-03-09
JP2011256193A (ja) 2011-12-22
CA2164866A1 (en) 1994-12-22
EP0702561A1 (de) 1996-03-27
EP1166793A1 (de) 2002-01-02
ES2335281T3 (es) 2010-03-24
EP1941898A2 (de) 2008-07-09
US20050129716A1 (en) 2005-06-16
CA2164866C (en) 2001-09-11
JP2010111703A (ja) 2010-05-20
CA2332406A1 (en) 1994-12-22
DE69435254D1 (de) 2009-12-31
CA2310845C (en) 2001-05-15
EP1508336A1 (de) 2005-02-23
ES2335662T3 (es) 2010-03-31
JP2005281317A (ja) 2005-10-13
DE69429619D1 (de) 2002-02-14
DE122009000066I1 (de) 2010-02-04
AU689115B2 (en) 1998-03-26
EP1941898B1 (de) 2010-03-17
WO1994028922A1 (en) 1994-12-22
EP1374886B1 (de) 2009-09-02
HK1061648A1 (en) 2004-09-30
EP1374886A3 (de) 2004-02-11
ES2168302T3 (es) 2002-06-16
DE69429619T2 (de) 2002-09-12
DE69435235D1 (de) 2009-10-15
EP1941898A3 (de) 2008-11-05
DE122009000066I2 (de) 2010-12-30
US20020010138A1 (en) 2002-01-24
EP1099445A3 (de) 2001-09-05
CA2310845A1 (en) 1994-12-22

Similar Documents

Publication Publication Date Title
DE69435253D1 (de) Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
DE69432299D1 (de) Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
DE69024039D1 (de) Behandlung von pathologischen zuständen und krankheiten.
DE69220679T2 (de) Antibakterielles mittel und behandlung von gegenständen mit diesem
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
ATE218360T1 (de) Behandlung von cerebraler ischämie und cerebralen verletzungen mit nervenschutzmitteln
DE69520296T2 (de) Oberflächenbehandlungsmittel und Oberflächenbehandlung von Halbleiter
DE69130437T2 (de) Gerät mit neuronalen Netzwerken zur Detektion und Behandlung von Arrythmien
DE69920019D1 (de) Behandlung von mineralfüllstoffen mit phosphaten, diese füllstoffe und deren verwendung
DE69426690T2 (de) Behandlung von atrophischer Haut und Vagina
DE59507427D1 (de) Mischkristalle und feste Lösungen von 1,4-Diketopyrrolopyrrolen
DE69422016D1 (de) Behandlung und entschwelfung von stahl in reformierungsverfahren mit niedrigem schwefelgehalt
DE69306335T2 (de) Prevention und Behandlung von Atherosclerosis
DE69306831T2 (de) Behandlung von Flüssigkeiten
DE69429259D1 (de) Behandlung von futtern und fasergut
AT400224B (de) Mittel zur behandlung und pflege von hufen
DE69501944D1 (de) Arzneimittel zur Vorbeugung oder Behandlung von chronischem Rheumatismus und Sepsis
DE69318644T2 (de) Behandlung von Flüssigkeiten
DE3881377D1 (de) Mittel zur prophylaxe und behandlung von thrombocytopenie.
DE69637316D1 (de) Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
DE9318429U1 (de) Mittel zur Abwehr und/oder Behandlung von Insektenstichen
DE59408477D1 (de) Therapieeinrichtung zur behandlung von leiden des herzens und herznaher gefässe
AU7319398A (en) Treatment of neuromuscular disorders and conditions with different botulinum serotype
NO944474D0 (no) Elektrisk stimulering for behandling av inkontinens og andre neuro-muskelforstyrrelser
DE9319102U1 (de) Pflanzliches Mittel zur Behandlung von Hämorrhoiden und analen Fissuren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition